Five-year Local Control in a Phase II Study of Hypofractionated Intensity Modulated Radiation Therapy With an Incorporated Boost for Early Stage Breast Cancer

被引:33
|
作者
Freedman, Gary M. [1 ]
Anderson, Penny R. [2 ]
Bleicher, Richard J. [4 ]
Litwin, Samuel [3 ]
Li, Tianyu [3 ]
Swaby, Ramona F. [5 ]
Ma, Chang-Ming Charlie [2 ]
Li, Jinsheng [2 ]
Sigurdson, Elin R. [4 ]
Watkins-Bruner, Deborah [6 ]
Morrow, Monica [7 ]
Goldstein, Lori J. [5 ]
机构
[1] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA
[2] Fox Chase Canc Ctr, Dept Radiat Oncol, Philadelphia, PA 19111 USA
[3] Fox Chase Canc Ctr, Dept Biostat, Philadelphia, PA 19111 USA
[4] Fox Chase Canc Ctr, Dept Surg Oncol, Philadelphia, PA 19111 USA
[5] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[6] Emory Univ, Sch Nursing, Atlanta, GA 30322 USA
[7] Mem Sloan Kettering Canc Ctr, Dept Surg Oncol, New York, NY 10021 USA
关键词
Breast boost; Breast cancer; Hypofractionation; IMRT; Radiation therapy; CONSERVING SURGICAL-PROCEDURES; QUALITY-OF-LIFE; RANDOMIZED-TRIAL; RADIOTHERAPY; WOMEN; IRRADIATION; SURGERY; FORM; RT;
D O I
10.1016/j.ijrobp.2012.01.091
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Conventional radiation fractionation of 1.8-2 Gy per day for early stage breast cancer requires daily treatment for 6-7 weeks. We report the 5-year results of a phase II study of intensity modulated radiation therapy (IMRT), hypofractionation, and incorporated boost that shortened treatment time to 4 weeks. Methods and Materials: The study design was phase II with a planned accrual of 75 patients. Eligibility included patients aged >= 18 years, Tis-T2, stage 0-II, and breast conservation. Photon IMRT and an incorporated boost was used, and the whole breast received 2.25 Gy per fraction for a total of 45 Gy, and the tumor bed received 2.8 Gy per fraction for a total of 56 Gy in 20 treatments over 4 weeks. Patients were followed every 6 months for 5 years. Results: Seventy-five patients were treated from December 2003 to November 2005. The median follow-up was 69 months. Median age was 52 years (range, 31-81). Median tumor size was 1.4 cm (range, 0.1-3.5). Eighty percent of tumors were node negative; 93% of patients had negative margins, and 7% of patients had close (>0 and <2 mm) margins; 76% of cancers were invasive ductal type: 15% were ductal carcinoma in situ, 5% were lobular, and 4% were other histology types. Twenty-nine percent of patients 29% had grade 3 carcinoma, and 20% of patients had extensive in situ carcinoma; 11% of patients received chemotherapy, 36% received endocrine therapy, 33% received both, and 20% received neither. There were 3 instances of local recurrence for a 5-year actuarial rate of 2.7%. Conclusions: This 4-week course of hypofractionated radiation with incorporated boost was associated with excellent local control, comparable to historical results of 6-7 weeks of conventional whole-breast fractionation with sequential boost. (C) 2012 Elsevier Inc.
引用
收藏
页码:888 / 893
页数:6
相关论文
共 50 条
  • [31] Simultaneous Integrated Boost Intensity Modulated Radiation Therapy in Early Breast Cancer Patients After Breast Conserving Surgery: A Prospective Study
    Qiao, X.
    Song, Y. Z.
    Zhen, C. J.
    Li, J.
    Liu, M.
    Zhou, Z. U.
    Wang, Y. X.
    Zhang, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E5 - E5
  • [32] Ultra-Hypofractionated Whole Breast Radiation Therapy Using a Novel Boost Regimen for Early-Stage Breast Cancer
    Chakraborty, M. A.
    Khan, A. J.
    Tadros, A. B.
    White, C.
    Kim, M.
    Zhang, Z.
    Braunstein, L. Z.
    Xu, A. J.
    LaPlant, Q.
    O'Brien, D. A. Roth
    Cuaron, J. J.
    Powell, S. N.
    Choi, I. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E301 - E302
  • [34] Prospective Study of Local Control and Late Radiation Toxicity After Intraoperative Radiation Therapy Boost for Early Breast Cancer
    Chang, David W.
    te Marvelde, Luc
    Chua, Boon H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (01): : 73 - 79
  • [35] Cosmetic Results and Acute Toxicity using Breast Intensity Modulated Radiation Therapy with Simultaneous integrated Boost in Patients with Early-stage Breast Cancer
    Ghaly, M.
    Li, J.
    Giorello, C.
    Graham, L.
    Serviss, D.
    Varvaro, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : S204 - S204
  • [36] The Impact of Radiation Oncologists on the Early Adoption of Hypofractionated Radiation Therapy for Early-Stage Breast Cancer
    Boero, Isabel J.
    Gillespie, Erin F.
    Hou, Jiayi
    Paravati, Anthony J.
    Kim, Ellen
    Einck, John P.
    Yashar, Catheryn
    Mell, Loren K.
    Murphy, James D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 97 (03): : 571 - 580
  • [37] Intensity Modulated Radiation Therapy With Integrated Boost After Breast Conservative Surgery in Breast Cancer Patients: A Prospective Study
    Peng, R.
    Wang, S.
    Li, Y.
    Song, Y.
    Wang, W.
    Jin, J.
    Liu, Y.
    Liu, X.
    Yu, Z.
    Ren, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S85 - S85
  • [38] Phase I/II study of hypofractionated intensity modulated radiotherapy (IMRT) for prostate cancer including simultaneously integrated boost (SIB).
    Chang, Michael G.
    Saraiya, Siddharth
    Mukhopadhyay, Nitai
    Anscher, Mitchell
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [39] Adjuvant breast inversely planned intensity-modulated radiotherapy with simultaneous integrated boost for early stage breast cancer Results from a phase II trial
    Meng, Jin
    Huang, Wenzhi
    Mei, Xin
    Yu, Xiaoli
    Pan, Ziqiang
    Ma, Jinli
    Ma, Xuejun
    Chen, Jiayi
    Guo, Xiaomao
    Yang, Zhaozhi
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (09) : 764 - 770
  • [40] Noninferiority of Local Control and Comparable Toxicity of Intensity Modulated Radiation Therapy With Simultaneous Integrated Boost in Breast Cancer: 5-Year Results of the IMRT-MC2 Phase III Trial
    Forster, Tobias
    Koehler, Clara
    Dorn, Melissa
    Haefner, Matthias Felix
    Arians, Nathalie
    Koenig, Laila
    Ben Harrabi, Semi
    Schlampp, Ingmar
    Weykamp, Fabian
    Meixner, Eva
    Lang, Kristin
    Heinrich, Vanessa
    Weidner, Nicola
    Huesing, Johannes
    Wallwiener, Markus
    Golatta, Michael
    Hennigs, Andre
    Heil, Jorg
    Hof, Holger
    Krug, David
    Debus, Jurgen
    Hoerner-Rieber, Juliane
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (04): : 857 - 868